US Food and Drug Administration-mandated trials of long-acting β-agonists safety in asthma: Will we know the answer?

Chest

Volumn 143, Issue 5, 2013, Pages 1208-1213

  Suissa, Samy ^a,b   Ariel, Amnon ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c HAEMEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG;

ASTHMA; DISEASE ASSOCIATION; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; INTUBATION; MEDICAL DECISION MAKING; MORTALITY; NOTE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SAMPLE SIZE; STUDY DESIGN; TREND STUDY; UNITED STATES;

EID: 84877622627     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2881     Document Type: Note

References (15)

1. Global strategy for asthma management and prevention. Global Initiative for Asthma website. http://www.ginasthma.org/uploads/users/files/GINA-Report- 2012.pdf. Updated-2012. Accessed February 21, 2013.
2. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306(6884):1034-1037. (Pubitemid 23105961)
3. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26. (Pubitemid 43265239)
4. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. Statistical briefing package for joint meeting of the Pulmonary-Allergy Drugs Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/ 08/briefing/2008-4398b1-01-FDA.pdf. Accessed March 8, 2013.
5. 2-adrenergic receptor agonists. Pediatrics. 2011;128(5): e1147-e1154.
6. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. 2009;33(1):21-32.
7. Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma: a systematic review. Pulm Pharmacol Ther. 2009;22(1):9-19.
8. Chowdhury BA, Dal Pan G. The FDA and safe use of longacting beta-agonists in the treatment of asthma. N Engl J Med. 2010;362(13):1169-1171.
9. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med. 2011;364(26):2473-2475.
10. Sears MR. The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility? Thorax. 2013; 68(2):195-198.
11. Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials. 2011;12:106.
12. Fleming TR. Current issues in non-inferiority trials. Stat Med. 2008;27(3):317-332. (Pubitemid 351227869)
13. Brozek JL, Kraft M, Krishnan JA, et al. Long-acting β2-agonist step-off in patients with controlled asthma: systematic review with meta-analysis. Arch Intern Med. 2012;172(18):1365-1375.
14. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008; 31(5):927-933.
15. Rodrigo GJ, Castro-Rodríguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax. 2012;67(4):342-349.